STUDY OF A TREND IN THE FREQUENCY OF USING MAIN DRUG CLASSES INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC CORONARY HEART DISEASE IN 2004 TO 2014: DATA FROM THE CHD PROGNOSIS REGISTRY

Objective: to estimate a trend in the frequency of using drugs with their proven effect on disease outcome in patients with chronic coronary heart disease (CHD) in 2004–2014 within the CHD PROGNOSIS registry.
Materials and methods. The investigation included data from the CHD PROGNOSIS registry on 303 patients with verified CHD during the 2004–2007 reference hospitalization at the National Research Center for Preventive Medicine, who made a control visit 4 years later, and those on 125 patients who had come following 7 years.
Results. There was a low frequency of prescribing the drugs that were able to improve prognosis in patients with stable CHD prior to the 2004–2007 reference hospitalization with an increase at discharge and with a further reduction during outpatient treatment. 7.6 and 86.5% of the patients took statins; 68 and 96 % received disaggregants; 24.8 and 94 % used β-adrenoblockers (β-AB), and 19 and 83 % had angiotensin-converting enzyme (ACE) inhibitors before hospitalization and at discharge, respectively (p < 0.001). Four and seven years after discharge, there were reductions in the frequency of using statins to 67 and 70 %, disaggregants to 80 and 90 %, β-AB to 80 and 75 %, and ACE inhibitors to 66 and 65 %, respectively (p < 0.01). At the same time, the above-mentioned drugs were taken by 15 and 69 % of patients on admission and at discharge, respectively (p < 0.001), by 41 and 35 % after 4 and 7 years (p < 0.01). In 2004 to 2014, most drugs were used at low and moderate doses with a gradual increase in the share of generics.
Conclusion. The therapy in patients with stable CHD was characterized by a low frequency of using the drugs with their proven effect on prognosis prior to the 2004–2007 reference hospitalization with an increase and a decrease in the frequency of their use on discharge and after 4 and 7 years. During 10 years, β-AB, ACE inhibitors/angiotensin II receptor antagonists, and statins were used mainly at low and moderate doses. Moreover, there was a gradual rise in the share of generics, in the use of statins in particular. 

1. Демографический ежегодник России, 2015. Доступно по ссылке: http://www.gks.ru/wps/wcm/connect/rosstat_ main/rosstat/ru/statistics/publications/ catalog/doc_1137674209312. [Demographic annual of Russia. 2015. Available at: http:// www.gks.ru/wps/wcm/connect/rosstat_main/ rosstat/ru/statistics/publications/catalog/ doc_1137674209312. (In Russ.)].

2. Task Force Members, Montalescot G., Sechtem U. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38):2949–3003.

3. Henderson R.A., O’Flynn N., Guideline Development Group. Management of stable angina: summary of NICE guidance. Heart 2012;98(6):500–7.

4. Capewell S., Critchley J.A., Unal B. IMPACT, a validated, comprehensive coronary heart disease model. Model overview & technical appendices. UK, Liverpool, 2007.

5. Flores-Mateo G., Grau M., O’Flaherty M. et al. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988–2005. Rev Esp Cardiol 2011;64(11):988–96.

6. Ford E.S., Ajani U.A., Croft J.B. et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356(23):2388–98.

7. Hotchkiss J.W., Davies C.A., Dundas R. et al. Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data. BMJ 2014;348:g1088.

8. Yusuf S., Islam S., Chow C.K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and lowincome countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378(9798):1231–43.

9. Оганов Р.Г., Погосова Г.В., Колтунов И.Е., и др. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть I. Кардиология 2007;47(5):58–66. [Oganov R.G., Pogosova G.V., Koltunov I.E. et al. RELIF – Regular Treatment And Prevention – a key to situation improvement with cardiovascular diseases in Russia: results Russian multicentre research. Pt I. Kardiologiya = Cardiology 2007;47(5):58–66. (In Russ.)].

10. Оганов Р.Г., Погосова Г.В., Колтунов И.Е., и др. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть II. Кардиология 2007;47(11):30–9. [Oganov R.G., Pogosova G.V., Koltunov I.E. et al. RELIF – Regular Treatment And Prevention – a key to situation improvement with cardiovascular diseases in Russia: results of the Russian multicenter research. Pt II. Kardiologiya = Cardiology 2007;47(11):30–9. (In Russ.)].

11. Оганов Р.Г., Погосова Г.В., Колтунов И.Е., и др. РЕЛИФ – Регулярное Лечение И проФилактика – ключ к улучшению ситуации с сердечно-сосудистыми заболеваниями в России: результаты российского многоцентрового исследования. Часть III. Кардиология 2008;48(4):46–53. [Oganov R.G., Pogosova G.V., Koltunov I.E. et al. RELIF – Regular Treatment And prevention – a key to situation improvement with cardiovascular diseases in Russia: results of the Russian multicenter research. Pt III. Kardiologiya = Cardiology 2008;48(4):46–53. (In Russ.)].

12. Сусеков А.В., Зубарева М.Ю., Деев А.Д и др. Основные результаты Московского Исследования по Статинам (Moscow Statin Survey, MSS). Сердце 2006;(6):324–8. [Susekov A.V., Zubareva M.Yu., Deev A.D. et al. Main results of the Moscow Research on Statines (to Moscow Statin Survey, MSS). Serdtse = Heart 2006;(6):324–8. (In Russ.)].

13. Шальнова С.А., Деев А.Д., Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врачакардиолога. Кардиоваскулярная терапия и профилактика 2006;5(2):73–80. [Shalnova S.A., Deev A.D., Karpov Yu.A. Arterial hypertension and coronary heart disease in real practice of the cardiologist. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2006;5(2):73–80. (In Russ.)].

14. Шальнова С.А., Деев A.Д. Уроки исследования ОСКАР – эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005–2006 г. Кардиоваскулярная терапия и профилактика 2007;6(1):47–53. [Shal’nova S.A., Deev A.D. Research lessons the OSCAR – epidemiology and features of therapy of patients of high risk in real clinical practice 2005–2006. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2007;6(1):47–53. (In Russ.)].

15. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP – Angina Treatment Pattern). Кардиология 2003;(5):9–15. [Oganov R.G., Lepakhin V.K., Fitilev S.B. et al. Features of diagnostics and therapy of stable stenocardia in the Russian Federation (the international research ATP – Angina Treatment Pattern). Kardiologiya = Cardiology 2003;(5):9–15. (In Russ.)].

16. Оганов Р.Г., Фитилев С.Б., Лепахин В.К. и др. Оценка выполнения рекомендаций по вторичной профилактике сердечно-сосудистых заболеваний у пациентов, перенесших инфаркт миокарда. Кардиоваскулярная терапия и профилактика 2009;8(4):71–5. [Oganov R.G., Fitilev S.B., Lepakhin V.K. et al. Assessment of implementation of recommendations about secondary prevention of cardiovascular diseases at the patients who have had a myocardial infarction. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2009;8(4):71–5. (In Russ.)].

17. Посненкова О.М., Киселев А.Р., Коротин А.С. и др. Публичный отчет о качестве медицинской помощи больным со стабильной ишемической болезнью сердца и хронической сердечной недостаточностью в 2013 году: данные регистра ишемической болезни сердца и хронической сердечной недостаточности по г. Саратову. Кардио-ИТ 2014;1(4):402. [Posnenkova O.M., Kiselev A.R., Korotin A.S. et al. The public report on quality of medical aid by the patient with stable ischemic illness of heart and chronic warm insufficiency in 2013: data of the register of ischemic heart disease and chronic heart failure on to Saratov. KardioIT = Cardio-IT 2014;1(4):402. (In Russ.)].

18. Гришунина А. Бюджет теряет 13 млрд рублей из-за того, что больные не принимают лекарства после высокотехнологичных операций. Медицинский Вестник. Портал Российского врача. Доступно по ссылке: http:// www.medvestnik.ru/content/Budjet-teryaet-13mlrd-rublei-iz-za-togo-chto-bolnye-neprinimaut-lekarstva-posle-vysokotehnologichnyh-operacii.html. [Grishunina А. Budget looses 13 billion rubles as the patients do not take drugs after high-tech surgeries. Medical Herald. Web portal of the Russian Physician. Available at: http://www.medvestnik. ru/content/Budjet-teryaet-13-mlrd-rublei-iz-zatogo-chto-bolnye-ne-prinimaut-lekarstva-poslevysokotehnologichnyh-operacii.html. (In Russ.)].

19. Бойцов С.А., Марцевич С.Ю., Кутишенко Н.П. и др. Регистры в кардиологии. Основные правила проведения и реальные возможности. Кардиоваскулярная терапия и профилактика 2013;12(1): 4–9. [Boytsov S.A., Martsevich S.Yu., Kutishenko N.P. et al. Registers in cardiology. Key rules of carrying out and real possibilities. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2013;12(1):4–9. (In Russ.)].

20. Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ИБС в реальной клинической практике по данным регистра «ПРОГНОЗ ИБС» (часть 1). Рациональная фармакотерапия в кардиологии 2013;9(2): 138–42. [Tolpygina S.N., Polyanskaya Yu.N., Martsevich S.Yu. Treatment of patients with chronic ischemic heart disease in real clinical practice according to the data from “PROGNOZ CHD” register (part 1). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2013;9(2):138–42. (In Russ.)].

21. Лукина Ю.В., Полянская Ю.Н., Толпыгина С.Н. и др. Изучение приверженности лечению статинами у пациентов с хронической ишемической болезнью сердца и соответствия гиполипидемической терапии клиническим рекомендациям (по данным регистра ПРОГНОЗ ИБС (Профилактическая медицина 2014;17(4):39–43. [Lukina Yu.V., Polyanskaya Yu.N., Тolpygina S.N. et al. Study of adherence to statin’s treatment at patients with chronic ischemic illness

22. of heart and conformity hypolipidemic therapies to clinical references (according to the register the ischemic heart disease PROGNOZ CHD). Profilakticheskaya meditsina = Preventive Medicine 2014;17(4):39–43. (In Russ.)].

23. Ершова А.И., Мешков А.Н., Якушин С.С. и др. Диагностика и лечение больных с выраженной гиперхолестеринемией в реальной амбулаторно-поликлинической практике (по данным регистра РЕКВАЗА). Рациональная фармакотерапия в кардиологии 2014;10(6):612–6. [Ershova A.I., Meshkov A.N., Yakushin S.S. et al. Diagnosis and treatment of patients with severe hypercholesterolemia in real outpatient practice (according to the RECVASA registry). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology 2014;10(6):612–6. (In Russ.)].

24. Толпыгина С.Н., Марцевич С.Ю., Гофман Е.А. и др. Опыт создания регистра для оценки исходов хронически протекающей ишемической болезни сердца: исследование «ПРОГНОЗ ИБС». Кардиоваскулярная терапия и профилактика 2013;12(1): 32–9. [Тolpygina S.N., Martsevich S.Yu., Gofman E.A. et al. Experience of building of the register for an assessment of outcomes of chronically proceeding ischemic heart disease: research “PROGNOZ CHD”. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention 2013;12(1):32–9. (In Russ.)].

25. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357(9261):995–1001.

26. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22(7):554–72.

27. Kotseva K., Wood D., De Backer G. et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16(2):121–37.

28. Kotseva K., Wood D., de Bacquer D. et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Cardiol 2016;23(6):636–48.

29. Панченко Е.П., Беленков Ю.Н. Характеристика и исходы атеротромбоза у амбулаторных больных в Российской Федерации (по материалам международного регистра REACH). Кардиология 2008;48(2): 17–24. [Panchenko E.P., Belenkov Yu.N. Characteristic and outcomes aterothrombosis at ambulatories in the Russian Federation (on stuffs of international register REACH). Kardiologiya = Cardiology 2008;48(2):17–24. (In Russ.)].

30. Шальнова С.А., Оганов Р.Г., Стэг Ф.Г., Форд Й. Ишемическая болезнь сердца. Современная реальность по данным всемирного регистра CLARIFY. Кардиология 2013;53(8):28–33. [Shal’nova S.A., Oganov R.G., Stag P.G., Ford J. Atherosclerotic heart disease. Modern reality according to data of the world register CLARIFY. Kardiologiya = Cardiology 2013;53(8):28–33. (In Russ.)].

31. Pfeffer M.A., McMurray J., Leizorovicz A. et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140(5):727–50.

32. Аронов Д.М. Как эффективно применять статины. Медицинский совет 2007;(1):41–5. [Aronov D.M. How effectively to use of statins. Meditsinskiy sovet = Medical Councillium 2007;(1):41–5. (In Russ.)].